CN114599374A - 用于增强抗癌化合物e7766的治疗依从性的系统 - Google Patents

用于增强抗癌化合物e7766的治疗依从性的系统 Download PDF

Info

Publication number
CN114599374A
CN114599374A CN202080061033.0A CN202080061033A CN114599374A CN 114599374 A CN114599374 A CN 114599374A CN 202080061033 A CN202080061033 A CN 202080061033A CN 114599374 A CN114599374 A CN 114599374A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080061033.0A
Other languages
English (en)
Chinese (zh)
Inventor
姜蓉嵘
V·迪克西特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN114599374A publication Critical patent/CN114599374A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080061033.0A 2019-07-01 2020-07-01 用于增强抗癌化合物e7766的治疗依从性的系统 Pending CN114599374A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869389P 2019-07-01 2019-07-01
US62/869,389 2019-07-01
PCT/US2020/040515 WO2021003279A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound e7766

Publications (1)

Publication Number Publication Date
CN114599374A true CN114599374A (zh) 2022-06-07

Family

ID=71895194

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080061033.0A Pending CN114599374A (zh) 2019-07-01 2020-07-01 用于增强抗癌化合物e7766的治疗依从性的系统

Country Status (10)

Country Link
US (1) US12564600B2 (https=)
EP (1) EP3993809B1 (https=)
JP (1) JP7704690B2 (https=)
KR (1) KR20220029717A (https=)
CN (1) CN114599374A (https=)
AU (1) AU2020300543A1 (https=)
BR (1) BR112021026876A2 (https=)
CA (1) CA3145824A1 (https=)
MX (1) MX2022000052A (https=)
WO (1) WO2021003279A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115512788A (zh) * 2022-09-16 2022-12-23 山东大学 一种运用pbpk模型预测sglt抑制剂人体暴露量及对靶部位蛋白抑制率的方法及系统

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024533394A (ja) 2021-09-09 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｓｔｉｎｇアゴニストのバイオマーカー及びその使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) * 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
US20180237468A1 (en) * 2017-02-17 2018-08-23 Eisai R&D Management Co., Ltd. Compounds for the Treatment of Cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516423A (ja) 2012-05-07 2015-06-11 ノバルティス アーゲー アリスポリビルによる薬物動態の調節
PL3265565T3 (pl) 2015-03-04 2021-01-25 Board Of Regents, The University Of Texas System Sposoby leczenia nowotworu z hemizygotyczną utratą tp53
JP2019512233A (ja) 2016-03-10 2019-05-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
KR102512494B1 (ko) 2017-06-30 2023-03-22 교와 가부시키가이샤 의약
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) * 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
US20180237468A1 (en) * 2017-02-17 2018-08-23 Eisai R&D Management Co., Ltd. Compounds for the Treatment of Cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARIA KARLGREN等: "Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug− Drug Interactions", J. MED. CHEM., vol. 55 *
黄九九等: "有机阴离子转运多肽及其对药物吸收、分布和排出的影响", 今日药学, vol. 20, no. 12, pages 1 - 2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115512788A (zh) * 2022-09-16 2022-12-23 山东大学 一种运用pbpk模型预测sglt抑制剂人体暴露量及对靶部位蛋白抑制率的方法及系统
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Also Published As

Publication number Publication date
AU2020300543A1 (en) 2022-02-24
JP2022538898A (ja) 2022-09-06
MX2022000052A (es) 2022-04-06
EP3993809B1 (en) 2024-10-09
EP3993809A1 (en) 2022-05-11
BR112021026876A2 (pt) 2022-02-22
KR20220029717A (ko) 2022-03-08
US12564600B2 (en) 2026-03-03
WO2021003279A1 (en) 2021-01-07
US20220304982A1 (en) 2022-09-29
CA3145824A1 (en) 2021-01-07
JP7704690B2 (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
EP1878444A1 (en) Composition containing antidementia agent
EP3503923B1 (en) Combination therapies for the treatment of hepatocellular carcinoma
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
RU2764724C2 (ru) Комбинированная терапия для лечения рака молочной железы
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
JP7704690B2 (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
KR20160110395A (ko) 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
Lavan et al. Development of a pediatric mini-tablet formulation for expedited preclinical studies
RU2820595C2 (ru) Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы
BR112017004948B1 (pt) Formulação farmacêutica, e, uso de uma formulação farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination